Actualités

Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 bill

The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part of a previously signed agreement, it stated. Register for our weekly newsletter HERE “We are […] The post Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease appeared first on ExecEdge.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in. On May 22, Denali Therapeutics Inc. (NASDAQ:DNLI) halted its joint work with Biogen Inc. (NASDAQ:BIIB), around the development of BIIB122 for idiopathic Parkinson’s disease. The decision came after topline results from the Phase 2b LUMA trial showed that […]

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

In early June 2026, Biogen reported that the FDA granted Breakthrough Therapy Designation to its investigational SMA treatment salanersen, while also, alongside UCB, presenting additional positive Phase 3 data for lupus candidate dapirolizumab pegol at the EULAR 2026 Congress. Together, these developments highlight Biogen’s expanding late-stage pipeline in severe neuromuscular and autoimmune diseases, with salanersen’s once-yearly dosing and dapirolizumab pegol’s steroid-sparing potential...

Biogen (BIIB) is back in focus after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, while fresh Phase 3 lupus data with partner UCB highlighted dapirolizumab pegol’s clinical profile. See our latest analysis for Biogen. Biogen’s recent FDA breakthrough designation for salanersen and fresh lupus data arrive as the share price trades at US$196.45, with a 90-day share price return of 6.26% and a 1-year total shareholder return of 50.70%,...

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.

Biogen and Denali Therapeutics have discontinued development of BIIB122 for early-stage Parkinson's disease. The decision follows Phase 2b LUMA trial results, where BIIB122 did not meet efficacy endpoints. The outcome affects Biogen's efforts in neurodegenerative diseases and LRRK2 inhibitor research. For investors tracking NasdaqGS:BIIB, the update comes with the stock trading at $192.23. The shares are up 46.6% over the past year but down 36.4% over three years and down 51.4% over five...

In May 2026, COMPASS Pathways plc elected Kathleen Tregoning to its Board of Directors, with plans for her to join the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee, alongside issuing new option grants to multiple directors including Tregoning. Tregoning’s background in corporate affairs, commercial strategy and late-stage biotech scaling at Cerevel Therapeutics, Sanofi and Biogen introduces additional commercialization and policy...

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA study failed to meet its endpoints. Legal investigations have been launched into Biogen following missed endpoints in the Phase 2 CELIA study for Alzheimer's therapy diranersen. These developments affect Biogen's pipeline in neurodegenerative diseases and add legal and regulatory scrutiny around its R&D disclosures. For investors following NasdaqGS:BIIB, the halt of BIIB122...

DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.

The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said.

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...

Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...